SCHEMBL13610955

SCHEMBL13610955

CC(C)(C)OC(=O)N1CC[C@@H](CNC(=O)c2cc(N)c(Br)c3c2OCCO3)C(O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
USP30 Q70CQ3 4/20 0.36
UTS2R Q9UKP6 2/20 0.35
IL1B P01584 1/20 0.35
P2RX7 Q99572 1/20 0.35
ACKR3 P25106 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
EED O75530 1/20 0.35
RBBP4 Q09028 1/20 0.35
SUZ12 Q15022 1/20 0.35
EZH2 Q15910 1/20 0.35
AEBP2 Q6ZN18 1/20 0.35
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603086 1.00 KDM4E (0.39) KDM4EPKMIDO1TDO2USP30
SCHEMBL13610957 0.97 KDM4E (0.38) KDM4EPKMIDO1TDO2USP30
SCHEMBL13603089 0.97 KDM4E (0.38) KDM4EPKMIDO1TDO2USP30
SCHEMBL13610711 0.90 KDM4E (0.39) KDM4EPKMUSP30UTS2RIL1B
SCHEMBL13603084 0.90 KDM4E (0.39) KDM4EPKMUSP30UTS2RIL1B
SCHEMBL13603087 0.86 KDM4E (0.38) KDM4EPKMUSP30UTS2RIL1B
SCHEMBL13607545 0.86 IL1B (0.39) KDM4EPKMUTS2RIL1BP2RX7
SCHEMBL13600607 0.86 IL1B (0.39) KDM4EPKMUTS2RIL1BP2RX7
SCHEMBL13610956 0.86 KDM4E (0.38) KDM4EPKMUSP30UTS2RIL1B
SCHEMBL13610959 0.83 KDM4E (0.39) KDM4EPKMIDO1TDO2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed